

For Immediate Release

Genelex Corporation
3000 First Ave. Seattle, WA 98121
www.genelex.com

Contact: Howard Coleman,
425 825 2870
HColeman@genelex.com

**FDA ADDS “BLACK BOX” WARNING TO COUMADIN/WARFARIN:
Genelex DNA tests could prevent thousands of emergency room visits,
hospitalizations and deaths for Coumadin patients.**

(SEATTLE, WA) -- Patients who worry about the safety of their Coumadin (warfarin) prescription can now determine their individually safe levels – potentially saving themselves from “major or fatal bleeding.”

How?

The answer is in their genes.

Historically, physicians have not had genetic data on the 300,000 to 500,000 patients who start on Coumadin every year. As a result, trial and error prescribing often takes weeks or months to reach consistently safe and effective dosage levels – leaving patients vulnerable to stroke, heart attack, or deadly bleeding. The dangers for these events have not escaped FDA notice, and serious “Black Box” warning on Coumadin was recently mandated.

The “Black Box” warns of “major or fatal bleeding,” and notes that “Bleeding is more likely to occur during the starting period.” Genelex’s test reveals information from two specific genes that accurately forecast how patients will respond to Coumadin.

The concept of genetic testing to determine how individual patients process this dangerous drug is being enthusiastically embraced by the FDA. They’re supporting clinical trials for hundreds of warfarin patients to determine the extent to which genetic testing will get patients to their optimal dose faster, safer, and at less cost.

Genelex founder Howard Coleman says this is the perfect example of how pharmaceuticals will be prescribed in the future – based on the individual’s specific DNA rather than the “one size fits all method” used today. “DNA testing prior to, or in the

induction phase of warfarin therapy is the low hanging fruit in healthcare improvement.” Warfarin is responsible for 15% of all serious adverse drug reactions, is very difficult to prescribe, and according to Coleman “DNA testing reveals the most important and potentially deadly contributors to individual patient variation in dose requirement.”

The new test is available online at www.Genelex.com or by calling (800) 523-3080. Patients who order receive a DNA collection kit, return a cotton cheek swab and receive results, usually within a week, which they may share with their physicians or pharmacist. More comprehensive tests for hundreds of prescribed or over the counter medicines are also available.

Genelex Corporation is a DNA testing laboratory improving drug safety and efficacy for consumers and their health-care providers by combining DNA drug reaction testing and the GeneMedRx drug interaction software into a comprehensive prescribing solution.